HIV significantly affects sleep, with many affected people living in a state akin to chronic jet lag. A new study with Wits ...

This includes capturing roughly 50% of newer switching Crohn's patients across all lines of therapy in The U.S. We see ...

The addition of an investigational therapeutic cancer vaccine to first-line pembrolizumab exhibited activity among patients ...

First-in-Human Phase 1 data for allogeneic CAR-T cell therapy for NHL to be featured in oral session ...

Q3 2025 Earnings Call October 28, 2025 8:00 AM EDTCompany ParticipantsAlexis SmithWilliam Meury - CEO, President ...

Race Oncology Ltd (ASX:RAC, OTC:RAONF) has presented new preclinical data suggesting its (E,E)-bisantrene can both protect the heart and ...

NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) (the Company or TG Therapeutics) today announced its financial results for the third quarter of 2025, along with recent ...

FDA-Registered Home Laser Technology Gains Rapid Adoption During Winter Season as Year-End HSA/FSA Deadlines Drive 290% Search Surge-Podiatrists Report Clinical-Grade Results Without $2,500+ Professio ...

BRIUMVI is currently approved in the United States, as well as several countries outside of the U.S., as a one-hour intravenous (IV) infusion administered twice a year, following the starting dose, in ...

Syndax’s leadership in menin inhibition and CSF-1R inhibition – – Revumenib abstracts showcase compelling results in multiple acute leukemia subtypes across the R/R, frontline, and post-HSCT setting – ...

TG Therapeutics, Inc. (NASDAQ: TGTX), announced today that enrollment has completed in the randomized cohort of the Phase 3 ENHANCE trial evaluating a consolidated ...

Merck and Eisai Provide Update on Phase 3 LEAP-012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma ...